kt-2000AI / Rakovina Therap - LARVOL DELTA

Rakovina Therapeutics Announces $1.5 Million Private Placement (GlobeNewswire) - "Proceeds from the Offering will be used to advance Rakovina’s pipeline, with a primary focus on in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program and continued AI-driven lead optimization through the Company’s collaboration with Variational AI. Funds will also support advancement of the kt-3000 LNP formulation program through in vitro and in vivo characterization, ongoing kt-2000AI compound development, and the continued expansion of the Company’s AI-enabled drug discovery collaborations."

Financing • Oncology • Solid Tumor